Table 1_Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors

A systematic review and meta-analysis of six comparative cohort studies involving 1,631 patients with non-small cell lung cancer and bone metastases. The dataset includes pooled hazard ratios for survival outcomes and odds ratios for binary outcomes, comparing radiotherapy plus immune checkpoint inhibitors to immune checkpoint inhibitors alone. The analysis was conducted by Yingding Ruan and published on figshare in March 2026.

Use Cases

• Compare overall survival and progression-free survival outcomes based on pooled hazard ratios.
• Assess the impact on skeletal-related events based on the reported odds ratio.
• Evaluate the safety profile by analyzing the odds ratio for grade ≥3 adverse events.
• Inform clinical trial design by examining the heterogeneity and quality of existing observational evidence.

Strengths

• Includes data from six studies with a total of 1,631 patients.
• Reports specific pooled effect sizes (e.g., HR 0.58 for OS, HR 0.44 for PFS) with confidence intervals.
• Assesses multiple outcomes: OS, PFS, ORR, AEs, and SREs.
• Study quality was evaluated using the Newcastle-Ottawa Scale.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The analysis is based on observational studies, which the authors note are of low to moderate quality.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, Cochrane Library, Web of Science, Scopus, and Embase.

Time Range

Studies published between January 2010 and October 2025.

Freshness

Last updated 2026-03-17 13:09:23; freshness should be verified.

Geography

null